Structure, Catalytic Mechanism, and Membrane Interaction of the Mtor Activator Rheb

Total Page:16

File Type:pdf, Size:1020Kb

Structure, Catalytic Mechanism, and Membrane Interaction of the Mtor Activator Rheb Structure, catalytic mechanism, and membrane interaction of the mTOR activator Rheb by Mohammad Taghi Mazhab Jafari A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Department of Medical Biophysics University of Toronto © Copyright by Mohammad Taghi Mazhab Jafari 2014 Structure, catalytic mechanism, and membrane interaction of the mTOR activator Rheb Mohammad Taghi Mazhab Jafari Doctor of Philosophy Department of Medical Biophysics University of Toronto 2014 Abstract The activator of mammalian target of rapamycin complex 1 (mTORC1), Ras homolog enriched in brain (Rheb), is a membrane-associated protein belonging to the Ras subfamily of small GTPases. Rheb’s slow GTPase activity is stimulated by the GTPase activating protein (GAP) domain of tuberous sclerosis complex 1 and 2 (TSC1/2). Rheb hyperactivation, through its overexpression or loss of TSC1/2 GAP function, results in hyperactivated mTORC1 signaling culminating in tumourigenesis. The molecular details of Rheb GTP hydrolysis and the effect of membrane association on Rheb structure, dynamics and its GTPase function are currently not fully understood. The studies presented in this thesis focus on two key determinants of Rheb function i) the mechanism of Rheb GTP hydrolysis and ii) the structural and functional consequence of Rheb-bilayer membrane interaction. Through studies of fluorescent nucleotides, we revealed that the conserved G2-box residue Tyr35 auto-inhibits GTP hydrolysis in Rheb. We demonstrated that a non-canonical catalytic residue, Asp65, in the switch II region of Rheb, contributed more to the GTP hydrolysis rate than Gln64, which corresponds to the canonical Ras Gln61. This non-canonical auto-inhibited mechanism of GTP hydrolysis was required for optimal mTORC1 regulation. These structural insights were then used to guide the design of novel gain- and loss-of function mutants by substitutions of the ultra-conserved G3-box Gly63 of Rheb. Finally, using solution ii NMR spectroscopy, we monitored the Rheb GTPase cycle and characterized its nucleotide-dependent membrane orientations on nanodisc-based phospholipid bilayers. Rheb was shown to sample two orientations in which its C-terminal helix was semi-perpendicular or semi-parallel with respect to the bilayer plane. The semi-parallel orientation, where switch II residues critical for mTORC1 communication are accessible, was favored in the GTP bound conformation, suggesting that membrane- tethering modulates Rheb function. These structural insights into the catalytic machinery of Rheb and its membrane interface suggest new approaches to modulate these key determinants of Rheb function through small molecules towards development of therapeutic avenues for Rheb-mediated pathogenesis such as tuberous sclerosis or cancer. iii Acknowledgments First and foremost, I would like to thank my supervisor Dr. Mitsu Ikura for his guidance, support, and understanding. I could have not accomplished any portion of this research without his supervision. His passion for science was a continuous source of inspiration for me over the years. I learned key aspects of successful research from him, including critical thinking. I am grateful to my supervisory committee members; Dr. Lewis Kay and Dr. Vuk Stambolic. Their expert inputs were critical to the success of this thesis. Thank you for your advise, supervision and encouragement, which kept me on the right path. I am also thankful to my collaborators, Vanessa De Palma and Jason Ho from Dr. Stambolic lab for the cell biology experiments. I had the honor of working with and learning from many excellent current and former members of Ikura’s lab including; Dr. Christopher Marshall, Dr. Peter Stathopulos, Dr. Genevieve Seabrook, Dr. Noboru Ishiyama, Le Zheng, Dr. Feng Wang, Carol Liu, and Dr. Fernando Amador. I would like to specially thank Chris, who was involved in all aspects of my projects and gave valuable inputs and suggestions. Finally, I would like to thank my family; my parents Mohammad Mazhab-Jafari and Ziba Fadavi and my brother Hamed Mazhab-Jafari for all their sacrifice that provided me with the opportunity to carry out this research. Words cannot express my grateful feelings for you. iv Table of Contents Acknowledgements……………………………………………………………………………………….iv Table of Contents ………………………………………………………………………………………...v List of Tables …………………………………………………………………………………………….x List of Figures …………………………………………………………………………………………...xi List of Appendices ……………………………………………………………………………………...xiv List of Abbreviations …………………………………………………………………………………...xv Chapter 1: Introduction and Thesis Overview ………………………………………………………...1 1.1 General introduction to small GTPase proteins……………………………………………………….2 1.2 Introduction to Rheb………………………………………………………………..............................3 1.3 Biophysical and biochemical properties of Rheb…………………………………..............................6 1.4 Pathogenesis of Rheb………………………………………………………………………………….9 1.5 Thesis Overview and Rationale……………………………………………………………………...11 1.6 Attributions…………………………………………………………………………………………..12 1.7 References……………………………………………………………………………………………12 Chapter 2: Fluorescent-tagged Nucleotides Alter the Native GTPase Cycle …………………….…17 2.1 Abstract………………………………………………………………………………………………18 2.2 Introduction………………………………………………………………………..............................19 2.3 Results………………………………………………………………………………………………..20 2.3.1 The effect of mant on the intrinsic rate of nucleotide hydrolysis………………………….20 v 2.3.2 The effect of mant on the rate of GAP-catalyzed nucleotide hydrolysis…………………..23 2.3.3 The effect of mant on the GEF-mediated nucleotide exchange…………………………....25 2.4 Discussion……………………………………………………………………………………………28 2.4.1 Intrinsic hydrolysis of GTP and mantGTP………………………………………………...28 2.4.2 GAP-catalyzed GTP hydrolysis by HRas and Rheb…………………………………….…30 2.4.3 GEF-accelerated nucleotide exchange of HRas and RhoA………………………………..31 2.5 Experimental Procedures…………………………………………………………………………….32 2.5.1 Protein preparation…………………………………………………………………………32 2.5.2 NMR-based GTPase, GAP and GEF assays……………………………………………….33 2.5.3 Fluorescence-based GTPase assay…………………………………………………………34 2.6 References……………………………………………………………………………………………34 Chapter 3: Mechanism of GTP hydrolysis by Rheb ……………………………………………..…...36 3.1 Abstract…………………………………………………………………………………………..…..37 3.2 Introduction………………………………………………………………………………………..…38 3.3 Results………………………………………………………………………………………………..39 3.3.1 Rheb Tyr35 inhibits intrinsic GTPase activity……………………………………………..39 3.3.2 Structural basis for the Tyr35 auto-inhibitory function……………………………………40 3.3.3 Identification of a catalytic residue for GTP hydrolysis…………………………………...42 3.3.4 Involvement of Rheb’s Asp65 and Tyr35 in TSC2GAP-mediated GTP hydrolysis…......47 3.3.5 Thermodynamic basis for the Tyr35 auto-inhibitory function…………………………….49 vi 3.3.6 Regulation of mTORC1 by growth factors involves the non-canonical catalytic and autoinhibitory mechanisms…………………………………………………………….………...54 3.4 Discussion……………………………………………………………………………………….…...57 3.5 Experimental Procedures……………………………………………………………………….……60 3.5.1 Protein preparation………………………………………………………………….……...60 3.5.2 Crystallization and data collection………………………………………………….……...61 3.5.3 Structure determination and refinement…………………………………………….……...61 3.5.4 NMR-based GTPase assays…………………………………………………………….…62 3.5.5 Thermodynamic measurements……………………………………………………….…..63 3.5.6 Cell-based phosphorylation assay……………………………………………………..…...63 3.5.7 Nucleotide binding in vivo…………………………………………………………………64 3.6 References……………………………………………………………………………………………65 Chapter 4: Structure-guided design of novel active and inactive Rheb mutants using single site modifications ……………………………………………………………………………………………68 4.1 Abstract……………………………………………………………………………………………....69 4.2 Introduction…………………………………………………………………………………………..70 4.3 Results and Discussion……………………………………………………………………………....72 4.4 Experimental Procedures…………………………………………………………………………….78 4.4.1 Protein Preparation…………………………………………………………………………78 4.4.2 NMR-based Real-time GTPase assay……………………………………………………...78 4.4.3 Crystallization and Data Collection………………………………………………………..79 vii 4.4.4 Structure Determination and Refinement………………………………………………….79 4.4.5 Cell-based Phosphorylation Assays………………………………………………………..80 4.5 References……………………………………………………………………………………………82 Chapter 5: Structural and Functional consequence of Rheb-membrane interaction ……………...84 5.1 Abstract………………………………………………………………………………………………85 5.2 Introduction…………………………………………………………………………………………..86 5.3 Results and Discussion………………………………………………………………………………88 5.4 Experimental Procedures……………………………………………………………………….……99 5.4.1 Protein preparations………………………………………………………………….…….99 5.4.2 Preparation of Rheb-nanodisc complex…………………………………………………..100 5.4.3 NMR- measurements……………………………………………………………………..101 5.4.4 Real-time NMR-based GTPase assay………………………………………………….…103 5.4.5 Molecular docking simulation……………………………………………………………103 5.5 References……………………………………………………………………………………….….106 Chapter 6: Conclusions and Future directions ……………...………………………………………108 6.1 Conclusions…………………………………………………………………………………………109 6.2 Future Directions…………………………………………………………………………………...110 6.2.1 Engineering GTPase probes by structure-guided mutations of G3-box glycine………....110 6.2.2 Drugging Rheb……………………………………………………………………………111 6.2.3 Probing membrane-dependent regulation of KRas-effector interaction………………….111 viii 6.3 Closing Remarks……………………………………………………………………………………112 6.4 References…………………………………………………………………………………………..114 Appendix A……………………………………………………………………………………………..116
Recommended publications
  • Adaptive Stress Signaling in Targeted Cancer Therapy Resistance
    Oncogene (2015) 34, 5599–5606 © 2015 Macmillan Publishers Limited All rights reserved 0950-9232/15 www.nature.com/onc REVIEW Adaptive stress signaling in targeted cancer therapy resistance E Pazarentzos1,2 and TG Bivona1,2 The identification of specific genetic alterations that drive the initiation and progression of cancer and the development of targeted drugs that act against these driver alterations has revolutionized the treatment of many human cancers. Although substantial progress has been achieved with the use of such targeted cancer therapies, resistance remains a major challenge that limits the overall clinical impact. Hence, despite progress, new strategies are needed to enhance response and eliminate resistance to targeted cancer therapies in order to achieve durable or curative responses in patients. To date, efforts to characterize mechanisms of resistance have primarily focused on molecular events that mediate primary or secondary resistance in patients. Less is known about the initial molecular response and adaptation that may occur in tumor cells early upon exposure to a targeted agent. Although understudied, emerging evidence indicates that the early adaptive changes by which tumor cells respond to the stress of a targeted therapy may be crucial for tumo r cell survival during treatment and the development of resistance. Here we review recent data illuminating the molecular architecture underlying adaptive stress signaling in tumor cells. We highlight how leveraging this knowledge could catalyze novel strategies to minimize
    [Show full text]
  • Regulation of the Mammalian Target of Rapamycin Complex 2 (Mtorc2)
    Regulation of the Mammalian Target Of Rapamycin Complex 2 (mTORC2) Inauguraldissertation Zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Klaus-Dieter Molle aus Heilbronn, Deutschland Basel, 2006 Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät Auf Antrag von Prof. Michael N. Hall und Prof. Markus Affolter. Basel, den 21.11.2006 Prof. Hans-Peter Hauri Dekan Summary The growth controlling mammalian Target of Rapamycin (mTOR) is a conserved Ser/Thr kinase found in two structurally and functionally distinct complexes, mTORC1 and mTORC2. The tumor suppressor TSC1-TSC2 complex inhibits mTORC1 by acting on the small GTPase Rheb, but the role of TSC1-TSC2 and Rheb in the regulation of mTORC2 is unclear. Here we examined the role of TSC1-TSC2 in the regulation of mTORC2 in human embryonic kidney 293 cells. Induced knockdown of TSC1 and TSC2 (TSC1/2) stimulated mTORC2-dependent actin cytoskeleton organization and Paxillin phosphorylation. Furthermore, TSC1/2 siRNA increased mTORC2-dependent Ser473 phosphorylation of plasma membrane bound, myristoylated Akt/PKB. This suggests that loss of Akt/PKB Ser473 phosphorylation in TSC mutant cells, as reported previously, is due to inhibition of Akt/PKB localization rather than inhibition of mTORC2 activity. Amino acids and overexpression of Rheb failed to stimulate mTORC2 signaling. Thus, TSC1-TSC2 also inhibits mTORC2, but possibly independently of Rheb. Our results suggest that mTORC2 hyperactivation may contribute to the pathophysiology of diseases such as cancer and Tuberous Sclerosis Complex. i Acknowledgement During my PhD studies in the Biozentrum I received a lot of support from many people around me who I mention here to express my gratefulness.
    [Show full text]
  • Lymphocyte/WBC-Based Comprehensive Testing Via Next-Gen Sequencing NF1/SPRED1 and Other Rasopathy Related Conditions on Blood/Saliva
    Last Updated October 2019 Institutional Price TAT Genetic Test CPT Codes Z codes Specimen Requirements (USD$) (working days) Lymphocyte/WBC-based Comprehensive Testing via Next-Gen Sequencing NF1/SPRED1 and Other RASopathy Related Conditions on Blood/Saliva NF1- only NGS testing and copy number analysis for the NF1 gene (NF1-NG) This testing includes an average coverage of >1600x to allow for the identification of (1) 3-6ml whole blood in EDTA (purple topped) tubes mosaicism as low as 3-5% of the alleles. In addition, novel variants identified in the $1,000 81408 25 (2) Oragene 575 saliva kit (provided by the MGL) ZB6A9 NF1 gene will be confirmed via RNA-based analysis at no additional charge. RNA- $1,600 (RUSH) 81479 15 (RUSH) (3) DNA sample (25ul volume at 3ug, O.D. value at based testing will also be provided to non-founder, multigenerational families with 260:280 ≥1.8) “classic” NF1 at no additional charge if next-generation sequencing is found negative. (1) 3-6ml whole blood in EDTA (purple topped) tubes SPRED1-only NGS testing and copy number analysis for SPRED1 (SPD1-NG) $800 81405 25 (2) Oragene 575 saliva kit (provided by the MGL) This testing includes an average coverage of >1600x to allow for the identification of ZB6AC $1,400 (RUSH) 81479 15 (RUSH) (3) DNA sample (25ul volume at 3ug, O.D. value at mosaicism as low as 3-5% of the alleles after comprehensive NF1 analysis. 260:280 ≥1.8) NF1/SPRED1 NGS testing and copy number analysis for NF1 and SPRED1 (NFSP-NG) (1) 3-6ml whole blood in EDTA (purple topped) tubes 81408 This testing includes an average coverage of >1600x to allow for the identification of $1,100 25 (2) Oragene 575 saliva kit (provided by the MGL) 81405 ZB6A8 mosaicism as low as 3-5% of the alleles.
    [Show full text]
  • Role of Excess Inorganic Pyrophosphate in Primer-Extension Genotyping Assays
    Methods Role of Excess Inorganic Pyrophosphate in Primer-Extension Genotyping Assays Ming Xiao,1 Angie Phong,1 Kristen L. Lum,1 Richard A. Greene,2 Philip R. Buzby,2,3 and Pui-Yan Kwok1,4,5 1Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California 94143-0130, USA; 2PerkinElmer Life and Analytical Sciences, Inc., Boston, Massachusetts 02118-2512, USA We have developed and genotyped >15,000 SNP assays by using a primer extension genotyping assay with fluorescence polarization (FP) detection. Although the 80% success rate of this assay is similar to those of other SNP genotyping assays, we wanted to determine the reasons for the failures and find ways to improve the assay. We observed that the failed assays fell into three general patterns: PCR failure, excess of heterozygous genotypes, and loss of FP signal for one of the dye labels. After analyzing several hundred failed assays, we concluded that 5% of the assays had PCR failure and had to be redesigned. We also discovered that the other two categories of failures were due to misincorporation of one of the dye-terminators during the primer extension reaction as a result of primer shortening with a reverse reaction involving inorganic pyrophosphate, and to the quenching of R110-terminator after its incorporation onto the SNP primer. The relatively slow incorporation of R110 acycloterminators by AcycloPol compounds the problem with the R110 label. In this report, we describe the source of the problems and simple ways to correct these problems by adding pyrophosphatase, using quenching as part of the analysis, and replacing R110 by Texas red as one of the dye labels.
    [Show full text]
  • TSC1/TSC2 Signaling in the CNS ⇑ Juliette M
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector FEBS Letters 585 (2011) 973–980 journal homepage: www.FEBSLetters.org Review TSC1/TSC2 signaling in the CNS ⇑ Juliette M. Han, Mustafa Sahin The F.M. Kirby Neurobiology Center, Department of Neurology, Children’s Hospital Boston, Harvard Medical School, Boston, MA 02115, USA article info abstract Article history: Over the past several years, the study of a hereditary tumor syndrome, tuberous sclerosis complex Received 5 January 2011 (TSC), has shed light on the regulation of cellular proliferation and growth. TSC is an autosomal Revised 1 February 2011 dominant disorder that is due to inactivating mutations in TSC1 or TSC2 and characterized by benign Accepted 1 February 2011 tumors (hamartomas) involving multiple organ systems. The TSC1/2 complex has been found to play Available online 15 February 2011 a crucial role in an evolutionarily-conserved signaling pathway that regulates cell growth: the Edited by Wilhelm Just mTORC1 pathway. This pathway promotes anabolic processes and inhibits catabolic processes in response to extracellular and intracellular factors. Findings in cancer biology have reinforced the critical role for TSC1/2 in cell growth and proliferation. In contrast to cancer cells, in the CNS, the Keywords: mTOR TSC1/2 complex not only regulates cell growth/proliferation, but also orchestrates an intricate and Autism finely tuned system that has distinctive roles under different conditions, depending on cell type, Translation stage of development, and subcellular localization. Overall, TSC1/2 signaling in the CNS, via its multi-faceted roles, contributes to proper neural connectivity.
    [Show full text]
  • Mtor: a Pharmacologic Target for Autophagy Regulation
    mTOR: a pharmacologic target for autophagy regulation Young Chul Kim, Kun-Liang Guan J Clin Invest. 2015;125(1):25-32. https://doi.org/10.1172/JCI73939. Review mTOR, a serine/threonine kinase, is a master regulator of cellular metabolism. mTOR regulates cell growth and proliferation in response to a wide range of cues, and its signaling pathway is deregulated in many human diseases. mTOR also plays a crucial role in regulating autophagy. This Review provides an overview of the mTOR signaling pathway, the mechanisms of mTOR in autophagy regulation, and the clinical implications of mTOR inhibitors in disease treatment. Find the latest version: https://jci.me/73939/pdf The Journal of Clinical Investigation REVIEW SERIES: AUTOPHAGY Series Editor: Guido Kroemer mTOR: a pharmacologic target for autophagy regulation Young Chul Kim and Kun-Liang Guan Department of Pharmacology and Moores Cancer Center, UCSD, La Jolla, California, USA. mTOR, a serine/threonine kinase, is a master regulator of cellular metabolism. mTOR regulates cell growth and proliferation in response to a wide range of cues, and its signaling pathway is deregulated in many human diseases. mTOR also plays a crucial role in regulating autophagy. This Review provides an overview of the mTOR signaling pathway, the mechanisms of mTOR in autophagy regulation, and the clinical implications of mTOR inhibitors in disease treatment. Overview of mTOR signaling pathway such as insulin and IGF activate their cognate receptors (recep- Nutrients, growth factors, and cellular energy levels are key deter- tor tyrosine kinases [RTKs]) and subsequently activate the PI3K/ minants of cell growth and proliferation. mTOR, a serine/threon- AKT signaling axis.
    [Show full text]
  • Neuropeptidergic Signaling Partitions Arousal Behaviors in Zebrafish
    3142 • The Journal of Neuroscience, February 26, 2014 • 34(9):3142–3160 Behavioral/Cognitive Neuropeptidergic Signaling Partitions Arousal Behaviors in Zebrafish Ian G. Woods,1,2 David Schoppik,2 Veronica J. Shi,2 Steven Zimmerman,2 Haley A. Coleman,1 Joel Greenwood,3 Edward R. Soucy,3 and Alexander F. Schier2,3 1Department of Biology, Ithaca College, Ithaca, New York 14850, and 2Department of Molecular and Cellular Biology and 3Center for Brain Science, Harvard University, Cambridge, Massachusetts 02138 Animals modulate their arousal state to ensure that their sensory responsiveness and locomotor activity match environmental demands. Neuropeptides can regulate arousal, but studies of their roles in vertebrates have been constrained by the vast array of neuropeptides and their pleiotropic effects. To overcome these limitations, we systematically dissected the neuropeptidergic modulation of arousal in larval zebrafish. We quantified spontaneous locomotor activity and responsiveness to sensory stimuli after genetically induced expression of seven evolutionarily conserved neuropeptides, including adenylate cyclase activating polypeptide 1b (adcyap1b), cocaine-related and amphetamine-related transcript (cart), cholecystokinin (cck), calcitonin gene-related peptide (cgrp), galanin, hypocretin, and nocicep- tin. Our study reveals that arousal behaviors are dissociable: neuropeptide expression uncoupled spontaneous activity from sensory responsiveness, and uncovered modality-specific effects upon sensory responsiveness. Principal components analysis and phenotypic clustering revealed both shared and divergent features of neuropeptidergic functions: hypocretin and cgrp stimulated spontaneous locomotor activity, whereas galanin and nociceptin attenuated these behaviors. In contrast, cart and adcyap1b enhanced sensory respon- siveness yet had minimal impacts on spontaneous activity, and cck expression induced the opposite effects. Furthermore, hypocretin and nociceptin induced modality-specific differences in responsiveness to changes in illumination.
    [Show full text]
  • Mutational Spectrum of the TSC1 Gene in a Cohort of 225 Tuberous Sclerosis Complex Patients: J Med Genet: First Published As 10.1136/Jmg.36.4.285 on 1 April 1999
    J Med Genet 1999;36:285–289 285 Mutational spectrum of the TSC1 gene in a cohort of 225 tuberous sclerosis complex patients: J Med Genet: first published as 10.1136/jmg.36.4.285 on 1 April 1999. Downloaded from no evidence for genotype-phenotype correlation Marjon van Slegtenhorst, Senno Verhoef, Anita Tempelaars, Lida Bakker, Qi Wang, Marja Wessels, Remco Bakker, Mark Nellist, Dick Lindhout, Dicky Halley, Ans van den Ouweland Abstract TSC1 locus on chromosome 9q34 and the Tuberous sclerosis complex is an inherited other half to the TSC2 locus on chromosome tumour suppressor syndrome, caused by a 16p13.67 The TSC1 and TSC2 genes were mutation in either the TSC1 or TSC2 identified by positional cloning89 and there is gene. The disease is characterised by a abundant evidence that both genes act as broad phenotypic spectrum that can in- tumour suppressor genes.10–13 clude seizures, mental retardation, renal The TSC2 gene consists of 41 exons, dysfunction, and dermatological abnor- spanning 43 kb of genomic DNA.14 It encodes malities. The TSC1 gene was recently a 200 kDa protein, tuberin, which has a identified and has 23 exons, spanning 45 putative GAP activity for rab515 and rap1,16 two kb of genomic DNA, and encoding an 8.6 members of the ras superfamily of small kb mRNA. After screening all 21 coding GTPases. The mutational spectrum of TSC2 exons in our collection of 225 unrelated includes a number of large deletions often dis- 17 18 patients, only 29 small mutations were rupting the PKD1 gene as well, but also 19–27 detected, suggesting that TSC1 mutations point mutations and a number of missense 28 are under-represented among TSC pa- changes.
    [Show full text]
  • Mutation Analysis of Son of Sevenless in Juvenile Myelomonocytic Leukemia
    Letters to the Editor 1108 3 Licht JD. Reconstructing a disease: what essential features of the the development of acute promyelocytic leukemia in transgenic retinoic acid receptor fusion oncoproteins generate acute promye- mice. Proc Natl Acad Sci USA 2000; 97: 13306–13311. locytic leukemia? Cancer Cell 2006; 9: 73–74. 10 Sternsdorf T, Phan VT, Maunakea ML, Ocampo CB, Sohal J, 4 Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. Silletto A et al. Forced retinoic acid receptor alpha homodimers A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 prime mice for APL-like leukemia. Cancer Cell 2006; 9: 81–94. genes as a therapeutic target of imatinib in idiopathic hypereosino- 11 Kwok C, Zeisig BB, Dong S, So CW. Forced homo-oligomerization philic syndrome. N Engl J Med 2003; 348: 1201–1214. of RARalpha leads to transformation of primary hematopoietic 5 Kaufmann I, Martin G, Friedlein A, Langen H, Keller W. Human cells. Cancer Cell 2006; 9: 95–108. Fip1 is a subunit of CPSF that binds to U-rich RNA elements and 12 Palaniswamy V, Moraes KC, Wilusz CJ, Wilusz J. Nucleophosmin stimulates poly(A) polymerase. EMBO J 2004; 23: 616–626. is selectively deposited on mRNA during polyadenylation. Nat 6 Sainty D, Liso V, Cantu-Rajnoldi A, Head D, Mozziconacci MJ, Struct Mol Biol 2006; 13: 429–435. Arnoulet C et al. A new morphologic classification system for acute 13 Rego EM, Ruggero D, Tribioli C, Cattoretti G, Kogan S, Redner RL promyelocytic leukemia distinguishes cases with underlying PLZF/ et al.
    [Show full text]
  • Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association Between BMI and Adult-Onset Non- Atopic
    Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association between BMI and Adult-Onset Non- Atopic Asthma Ayoung Jeong 1,2, Medea Imboden 1,2, Akram Ghantous 3, Alexei Novoloaca 3, Anne-Elie Carsin 4,5,6, Manolis Kogevinas 4,5,6, Christian Schindler 1,2, Gianfranco Lovison 7, Zdenko Herceg 3, Cyrille Cuenin 3, Roel Vermeulen 8, Deborah Jarvis 9, André F. S. Amaral 9, Florian Kronenberg 10, Paolo Vineis 11,12 and Nicole Probst-Hensch 1,2,* 1 Swiss Tropical and Public Health Institute, 4051 Basel, Switzerland; [email protected] (A.J.); [email protected] (M.I.); [email protected] (C.S.) 2 Department of Public Health, University of Basel, 4001 Basel, Switzerland 3 International Agency for Research on Cancer, 69372 Lyon, France; [email protected] (A.G.); [email protected] (A.N.); [email protected] (Z.H.); [email protected] (C.C.) 4 ISGlobal, Barcelona Institute for Global Health, 08003 Barcelona, Spain; [email protected] (A.-E.C.); [email protected] (M.K.) 5 Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain 6 CIBER Epidemiología y Salud Pública (CIBERESP), 08005 Barcelona, Spain 7 Department of Economics, Business and Statistics, University of Palermo, 90128 Palermo, Italy; [email protected] 8 Environmental Epidemiology Division, Utrecht University, Institute for Risk Assessment Sciences, 3584CM Utrecht, Netherlands; [email protected] 9 Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College, SW3 6LR London, UK; [email protected] (D.J.); [email protected] (A.F.S.A.) 10 Division of Genetic Epidemiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; [email protected] 11 MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, W2 1PG London, UK; [email protected] 12 Italian Institute for Genomic Medicine (IIGM), 10126 Turin, Italy * Correspondence: [email protected]; Tel.: +41-61-284-8378 Int.
    [Show full text]
  • Tuberous Sclerosis Complex: Molecular Pathogenesis and Animal Models
    Neurosurg Focus 20 (1):E4, 2006 Tuberous sclerosis complex: molecular pathogenesis and animal models LEANDRO R. PIEDIMONTE, M.D., IAN K. WAILES, M.D., AND HOWARD L. WEINER, M.D. Division of Pediatric Neurosurgery, Department of Neurosurgery, New York University School of Medicine, New York, New York Mutations in one of two genes, TSC1 and TSC2, result in a similar disease phenotype by disrupting the normal inter- action of their protein products, hamartin and tuberin, which form a functional signaling complex. Disruption of these genes in the brain results in abnormal cellular differentiation, migration, and proliferation, giving rise to the charac- teristic brain lesions of tuberous sclerosis complex (TSC) called cortical tubers. The most devastating complications of TSC affect the central nervous system and include epilepsy, mental retardation, autism, and glial tumors. Relevant animal models, including conventional and conditional knockout mice, are valuable tools for studying the normal func- tions of tuberin and hamartin and the way in which disruption of their expression gives rise to the variety of clinical features that characterize TSC. In the future, these animals will be invaluable preclinical models for the development of highly specific and efficacious treatments for children affected with TSC. KEY WORDS • tuberous sclerosis • pathogenesis • animal model Tuberous sclerosis complex is an autosomal-dominant zures, mental retardation, and autism.1,51 The number and tumor predisposition syndrome that affects approximately location of cortical tubers and the patient’s age at seizure 1 in 7500 individuals worldwide.19 The TSC is character- onset are highly correlated with neurological outcomes.1,30 ized by benign hamartomatous growths in multiple organs, Epilepsy occurs in approximately 80% of affected indi- including the kidney, skin, retina, lung, and brain.
    [Show full text]
  • Figure S1. HAEC ROS Production and ML090 NOX5-Inhibition
    Figure S1. HAEC ROS production and ML090 NOX5-inhibition. (a) Extracellular H2O2 production in HAEC treated with ML090 at different concentrations and 24 h after being infected with GFP and NOX5-β adenoviruses (MOI 100). **p< 0.01, and ****p< 0.0001 vs control NOX5-β-infected cells (ML090, 0 nM). Results expressed as mean ± SEM. Fold increase vs GFP-infected cells with 0 nM of ML090. n= 6. (b) NOX5-β overexpression and DHE oxidation in HAEC. Representative images from three experiments are shown. Intracellular superoxide anion production of HAEC 24 h after infection with GFP and NOX5-β adenoviruses at different MOIs treated or not with ML090 (10 nM). MOI: Multiplicity of infection. Figure S2. Ontology analysis of HAEC infected with NOX5-β. Ontology analysis shows that the response to unfolded protein is the most relevant. Figure S3. UPR mRNA expression in heart of infarcted transgenic mice. n= 12-13. Results expressed as mean ± SEM. Table S1: Altered gene expression due to NOX5-β expression at 12 h (bold, highlighted in yellow). N12hvsG12h N18hvsG18h N24hvsG24h GeneName GeneDescription TranscriptID logFC p-value logFC p-value logFC p-value family with sequence similarity NM_052966 1.45 1.20E-17 2.44 3.27E-19 2.96 6.24E-21 FAM129A 129. member A DnaJ (Hsp40) homolog. NM_001130182 2.19 9.83E-20 2.94 2.90E-19 3.01 1.68E-19 DNAJA4 subfamily A. member 4 phorbol-12-myristate-13-acetate- NM_021127 0.93 1.84E-12 2.41 1.32E-17 2.69 1.43E-18 PMAIP1 induced protein 1 E2F7 E2F transcription factor 7 NM_203394 0.71 8.35E-11 2.20 2.21E-17 2.48 1.84E-18 DnaJ (Hsp40) homolog.
    [Show full text]